Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor/ivacaftor compared to males-Reference-Cited by-同舟云学术

Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor/ivacaftor compared to males

Published:2021-01 Issue:1 Volume:20 Page:e7-e11
ISSN:1569-1993
Container-title:Journal of Cystic Fibrosis
language:en
Short-container-title:Journal of Cystic Fibrosis

Author:

Aalbers B.L.,Hofland R.W.,Bronsveld I.,de Winter-de Groot K.M.,Arets H.G.M.,de Kiviet A.C.,van Oirschot-van de Ven M.M.M.,Kruijswijk M.A.,Schotman S.,Michel S.,van der Ent C.K.,Heijerman H.G.M.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health

Reference22 articles.

1. Cystic Fibrosis Foundation. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: cystic Fibrosis Foundation consensus report;Farrell;J Pediatr,2008

2. Durmowicz A.G., Witzmann K.A., et al. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience. Chest201; 143 (1): 14–18

3. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study;Rosenfeld;Lancet Respir Med,2018

4. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study;Davies;Lancet Respir Med,2016

5. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation;Accurso;N Engl J Med,2010

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world data confirm elexacftor/tezacaftor/ivacaftor modulators halves sweat chloride concentration in eligible people with cystic fibrosis;APMIS;2024-08-02

2. Sex differences in airway disease: estrogen and airway surface liquid dynamics;Biology of Sex Differences;2024-07-18

3. Prioritizing sexual and reproductive health research and care for people with cystic fibrosis: A 2023 workshop report from the Cystic Fibrosis Foundation Sexual Health, Reproduction, and Gender (SHARING) Research Working Group;Journal of Cystic Fibrosis;2024-07

4. Sex Differences Persist After Treatment With Ivacaftor in People With Cystic Fibrosis;CHEST;2024-06

5. Heterogeneity in response to Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis;Journal of Cystic Fibrosis;2024-05